Septerna (SEPN) Competitors $16.06 +0.06 (+0.38%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$16.12 +0.06 (+0.40%) As of 09/23/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SEPN vs. CGON, MOR, HCM, RARE, OGN, ALVO, KNSA, IMVT, GMTX, and MLYSShould you be buying Septerna stock or one of its competitors? The main competitors of Septerna include CG Oncology (CGON), MorphoSys (MOR), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), Organon & Co. (OGN), Alvotech (ALVO), Kiniksa Pharmaceuticals International (KNSA), Immunovant (IMVT), Gemini Therapeutics (GMTX), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. Septerna vs. Its Competitors CG Oncology MorphoSys HUTCHMED Ultragenyx Pharmaceutical Organon & Co. Alvotech Kiniksa Pharmaceuticals International Immunovant Gemini Therapeutics Mineralys Therapeutics Septerna (NASDAQ:SEPN) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment. Do analysts prefer SEPN or CGON? Septerna currently has a consensus price target of $26.75, indicating a potential upside of 66.56%. CG Oncology has a consensus price target of $56.00, indicating a potential upside of 52.59%. Given Septerna's higher probable upside, research analysts plainly believe Septerna is more favorable than CG Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80CG Oncology 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92 Does the media prefer SEPN or CGON? In the previous week, CG Oncology had 13 more articles in the media than Septerna. MarketBeat recorded 16 mentions for CG Oncology and 3 mentions for Septerna. Septerna's average media sentiment score of 0.63 beat CG Oncology's score of 0.53 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 0 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, SEPN or CGON? Septerna has higher earnings, but lower revenue than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Septerna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSepterna$1.08M662.92-$71.80M-$10.09-1.59CG Oncology$1.14M2,454.71-$88.04M-$1.77-20.73 Do institutionals & insiders believe in SEPN or CGON? 26.6% of CG Oncology shares are owned by institutional investors. 4.3% of Septerna shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is SEPN or CGON more profitable? Septerna has a net margin of -12,053.03% compared to CG Oncology's net margin of -15,945.17%. CG Oncology's return on equity of -19.37% beat Septerna's return on equity.Company Net Margins Return on Equity Return on Assets Septerna-12,053.03% -31.52% -23.65% CG Oncology -15,945.17%-19.37%-18.72% SummaryCG Oncology beats Septerna on 10 of the 16 factors compared between the two stocks. Get Septerna News Delivered to You Automatically Sign up to receive the latest news and ratings for SEPN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SEPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SEPN vs. The Competition Export to ExcelMetricSepternaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$713.36M$3.16B$5.76B$10.50BDividend YieldN/A2.36%5.53%4.57%P/E Ratio-1.5921.0475.9626.62Price / Sales662.92252.06473.7891.77Price / CashN/A46.3537.4661.85Price / Book1.709.7813.486.45Net Income-$71.80M-$52.73M$3.29B$271.57M7 Day Performance11.61%3.16%1.83%2.61%1 Month Performance33.94%4.69%4.00%7.28%1 Year PerformanceN/A16.37%75.89%29.60% Septerna Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SEPNSepterna1.4565 of 5 stars$16.06+0.4%$26.75+66.6%N/A$713.36M$1.08M-1.59N/AAnalyst UpgradeCGONCG Oncology2.5536 of 5 stars$37.59+1.5%$56.00+49.0%-4.3%$2.87B$1.14M-21.3061Insider TradeGap UpMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730HCMHUTCHMED2.3816 of 5 stars$16.27-2.4%$20.88+28.3%-3.1%$2.84B$630.20M0.001,811News CoverageAnalyst DowngradeRAREUltragenyx Pharmaceutical4.3856 of 5 stars$29.13-1.2%$81.50+179.8%-50.7%$2.81B$560.23M-5.271,294Positive NewsOGNOrganon & Co.4.5663 of 5 stars$10.68+1.0%$17.33+62.4%-46.4%$2.77B$6.40B3.964,000Positive NewsALVOAlvotech3.9816 of 5 stars$8.91+11.2%$14.00+57.1%-20.0%$2.69B$491.98M38.811,032Trending NewsAnalyst UpgradeGap UpHigh Trading VolumeKNSAKiniksa Pharmaceuticals International2.6524 of 5 stars$36.30+0.6%$41.17+13.4%+47.6%$2.69B$423.24M907.73220Positive NewsIMVTImmunovant2.0234 of 5 stars$15.43-1.0%$33.60+117.8%-47.4%$2.69BN/A-5.41120Positive NewsGMTXGemini TherapeuticsN/A$61.50+1.2%N/A+27.8%$2.66BN/A-61.5030MLYSMineralys Therapeutics2.8353 of 5 stars$38.29-1.3%$43.50+13.6%+228.8%$2.53BN/A-10.7228 Related Companies and Tools Related Companies CGON Competitors MOR Competitors HCM Competitors RARE Competitors OGN Competitors ALVO Competitors KNSA Competitors IMVT Competitors GMTX Competitors MLYS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SEPN) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Septerna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Septerna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
